Form 4 Galecto, Inc. For: Oct 09 Filed by: Schambye Hans T.
Galecto, Inc. (GLTO)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
GLTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLTO alerts
High impacting Galecto, Inc. news events
Weekly update
A roundup of the hottest topics
GLTO
News
- Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]Yahoo! Finance
- Galecto Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Galecto, Inc. (NASDAQ: GLTO) had its price target raised by analysts at Oppenheimer Holdings Inc. from $9.00 to $10.00. They now have an "outperform" rating on the stock.MarketBeat
- Galecto Strengthens Board of Directors with Appointment of Dr. Amy WechslerGlobeNewswire
- Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines [Yahoo! Finance]Yahoo! Finance
GLTO
Earnings
- 11/1/24 - Beat
GLTO
Sec Filings
- 11/7/24 - Form SC
- 11/7/24 - Form SC
- 11/1/24 - Form 10-Q
- GLTO's page on the SEC website